Eton Change To Netincome vs End Period Cash Flow Analysis
ETON Stock | USD 12.74 0.39 3.16% |
Eton Pharmaceuticals financial indicator trend analysis is much more than just examining Eton Pharmaceuticals latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Eton Pharmaceuticals is a good investment. Please check the relationship between Eton Pharmaceuticals Change To Netincome and its End Period Cash Flow accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eton Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in Eton Stock, please use our How to Invest in Eton Pharmaceuticals guide.
Change To Netincome vs End Period Cash Flow
Change To Netincome vs End Period Cash Flow Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Eton Pharmaceuticals Change To Netincome account and End Period Cash Flow. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Eton Pharmaceuticals' Change To Netincome and End Period Cash Flow is 0.87. Overlapping area represents the amount of variation of Change To Netincome that can explain the historical movement of End Period Cash Flow in the same time period over historical financial statements of Eton Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Eton Pharmaceuticals' Change To Netincome and End Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Change To Netincome of Eton Pharmaceuticals are associated (or correlated) with its End Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when End Period Cash Flow has no effect on the direction of Change To Netincome i.e., Eton Pharmaceuticals' Change To Netincome and End Period Cash Flow go up and down completely randomly.
Correlation Coefficient | 0.87 |
Relationship Direction | Positive |
Relationship Strength | Strong |
Change To Netincome
End Period Cash Flow
Most indicators from Eton Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Eton Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eton Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in Eton Stock, please use our How to Invest in Eton Pharmaceuticals guide.At this time, Eton Pharmaceuticals' Tax Provision is very stable compared to the past year. As of the 16th of December 2024, Enterprise Value is likely to grow to about 71.5 M, while Selling General Administrative is likely to drop about 12.9 M.
2023 | 2024 (projected) | Depreciation And Amortization | 901K | 783.6K | Interest Income | 323.2K | 244.8K |
Eton Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Eton Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Eton Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 17.1M | 26.3M | 27.5M | 25.0M | 31.7M | 26.6M | |
Other Current Liab | 1.4M | 1.2M | 1.4M | 3.7M | 9.0M | 9.5M | |
Total Current Liabilities | 2.0M | 3.8M | 4.6M | 6.5M | 16.2M | 17.1M | |
Total Stockholder Equity | 10.6M | 15.7M | 17.6M | 13.1M | 15.5M | 12.7M | |
Net Tangible Assets | 9.8M | 15.1M | 14.0M | 8.3M | 9.6M | 12.2M | |
Property Plant And Equipment Net | 1.3M | 1.0M | 219K | 260K | 150K | 142.5K | |
Net Debt | (7.5M) | (14.2M) | (7.7M) | (9.8M) | (16.0M) | (16.8M) | |
Retained Earnings | (64.2M) | (92.2M) | (94.1M) | (103.1M) | (104.1M) | (109.3M) | |
Accounts Payable | 575K | 2.3M | 1.8M | 1.8M | 1.8M | 1.6M | |
Cash | 12.1M | 21.3M | 14.4M | 16.3M | 21.4M | 19.7M | |
Non Current Assets Total | 2.1M | 1.6M | 3.9M | 5.0M | 4.9M | 2.9M | |
Non Currrent Assets Other | 61K | 40K | 21K | 12K | 10.8K | 10.3K | |
Other Assets | 61K | 232K | 21K | 12K | 10.8K | 10.3K | |
Long Term Debt | 4.5M | 6.8M | 5.3M | 5.4M | 6.2M | 4.0M | |
Cash And Short Term Investments | 12.1M | 21.3M | 14.4M | 16.3M | 21.4M | 19.7M | |
Retained Earnings Total Equity | (45.9M) | (64.2M) | (92.2M) | (103.1M) | (92.8M) | (97.5M) | |
Common Stock Shares Outstanding | 17.8M | 21.0M | 25.2M | 25.1M | 25.6M | 21.6M | |
Liabilities And Stockholders Equity | 17.1M | 26.3M | 27.5M | 25.0M | 31.7M | 26.6M | |
Non Current Liabilities Total | 4.6M | 6.9M | 5.3M | 5.5M | 22K | 20.9K | |
Capital Surpluse | 72.2M | 74.7M | 107.8M | 116.2M | 133.6M | 82.0M | |
Inventory | 380K | 1.2M | 550K | 557K | 911K | 572K | |
Other Current Assets | 2.1M | 4.2M | 6.4M | 1.3M | 1.1M | 1.1M | |
Other Stockholder Equity | 74.7M | 107.8M | 111.7M | 116.2M | 119.5M | 97.9M | |
Total Liab | 6.5M | 10.7M | 9.8M | 12.0M | 16.3M | 9.2M | |
Net Invested Capital | 15.1M | 22.7M | 24.3M | 19.5M | 20.9M | 19.2M | |
Property Plant And Equipment Gross | 1.3M | 1.0M | 219K | 260K | 545K | 479.5K | |
Total Current Assets | 15.0M | 24.7M | 23.6M | 20.0M | 26.8M | 23.7M | |
Net Working Capital | 13.0M | 20.9M | 19.0M | 13.5M | 10.6M | 13.2M | |
Short Term Debt | 133K | 280K | 1.4M | 1.0M | 5.4M | 5.6M | |
Intangible Assets | 725K | 575K | 3.6M | 4.8M | 4.7M | 5.0M | |
Property Plant Equipment | 1.3M | 1.0M | 219K | 72K | 64.8K | 61.6K |
Pair Trading with Eton Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eton Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eton Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Eton Stock
Moving against Eton Stock
0.91 | TTOO | T2 Biosystms | PairCorr |
0.9 | AMGN | Amgen Inc | PairCorr |
0.85 | PFE | Pfizer Inc Fiscal Year End 4th of February 2025 | PairCorr |
0.82 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
0.81 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
The ability to find closely correlated positions to Eton Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eton Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eton Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eton Pharmaceuticals to buy it.
The correlation of Eton Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eton Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eton Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eton Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eton Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in Eton Stock, please use our How to Invest in Eton Pharmaceuticals guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eton Pharmaceuticals. If investors know Eton will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eton Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.13) | Earnings Share (0.26) | Revenue Per Share 1.219 | Quarterly Revenue Growth (0.24) | Return On Assets (0.12) |
The market value of Eton Pharmaceuticals is measured differently than its book value, which is the value of Eton that is recorded on the company's balance sheet. Investors also form their own opinion of Eton Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eton Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eton Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eton Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eton Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eton Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eton Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.